Incyte Corporation
Nasdaq INCY · Wilmington, DE
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
Incyte Corporation is a clinical trial sponsor based in Wilmington, DE, listed as Nasdaq INCY. It has 59 active clinical trials with 22,233 planned participants, across 16 therapeutic areas. Since 2021 it has completed 116 trials and stopped 47 early.
Trial track record · since 2021
Financials · Nasdaq INCY
Pipeline · 59 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
6 approved drug applications with a product on the market.
Questions about Incyte Corporation
Incyte Corporation is lead sponsor of 59 active clinical trials on ClinicalTrials.gov, with 22,233 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 116 trials and stopped 47 early.
Incyte Corporation is based in Wilmington, DE and is listed as Nasdaq INCY. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Incyte Corporation; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-15.
Approve Suite is not affiliated with Incyte Corporation.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.